Fine-mapping of the *TMEM106B* locus identifies four haplotypes with differential

associations to neurodegeneration

AUTHORS:

Alex Salazar[1], Niccolò Tesi[1,2], Lydian Knoop[1], Martijn Huisman,[3,4] Natasja M. van Schoor,[3,4] Betty

Tijms[5,6], Jort Vijverberg[5,6], Sven van der Lee[1,6], Sanduni Wijesekera[1], Jana Krizova[1], Mikko

Hiltunen[7], Markus Damme[8], Leonard Petrucelli[9,10], Marcel Reinders[2], August B. Smit[11], Anke A.

Dijkstra[12,13], Marc Hulsman[1], ADGC, Bonn, CHARGE, EADB, EADI, FinnGen, GERAD,

GR@ACE/DEGESCO, PGC-ALZ, and Henne Holstege[1,3,4,14,15]

AFFILIATIONS

1. Section Genomics of Neurodegenerative Diseases and Aging, Department of Clinical

Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

2. Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands

3. Department of Epidemiology and Data Sciences, Amsterdam UMC location Vrije Universiteit

Amsterdam, The Netherlands

4. Amsterdam Public Health Research Institute, Aging & Later Life, Amsterdam, The Netherlands

5. Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC

location VUmc, Amsterdam, The Netherlands

6. Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

7. Institute of Biomedicine, University of Eastern Finland. Kuopio, Finland

8. Institute of Biochemistry, Christian-Albrechts-University Kiel, Otto-Hahn-Platz 9, Kiel, Germany

9. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA

10. Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences,

Jacksonville, FL, USA

11. Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive

Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The

Netherlands

12. Department of Pathology, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam,

Netherlands

13. Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands

14. VIB Center for Brain and Disease Research, Leuven, Belgium

15. Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium

CORRESPONDING AUTHOR:

Henne Holstege: h.holstege@amsterdamumc.nl

KEYWORDS

TMEM106B, Alzheimer's disease, Fine-mapping, Haplotypes, Long-read sequencing, Structural

variation, DNA methylation, Centenarians, Cognitive resilience, Extreme longevity

ABSTRACT

Genetic variation at the *TMEM106B* locus has been associated with Alzheimer's disease (AD)

and related neurodegenerative phenotypes, yet its haplotypic architecture remains incompletely

resolved. We refined the genetic landscape of *TMEM106B* by integrating AD-GWAS summary

statistics (~978K individuals) with haplotype analyses in 5,873 Dutch genomes including AD-

cases, age-matched controls, and cognitively healthy centenarians. In addition to the known

linkage disequilibrium (LD) block defining risk and protective haplotypes characterized by the

amino acid substitution at residue 185 (Threonine/Serine), we identify a second conditionally

independent LD block. Together these form four haplotypes (T1-T4), with T3 strongly enriched in

centenarians. Long-read whole-genome sequencing in 493 individuals reveals haplotype-specific

methylation patterns and structural variation, including a ~19 Kbp genomic rearrangement carried

by T3. These findings indicate that the *TMEM106B* locus comprises multiple haplotypes defined

by methylation patterns and structural variants, offering insights into GWAS associations with AD

risk and cognitive longevity.

INTRODUCTION

TMEM106B plays an important role in maintaining cognitive health during aging. Genome-wide association studies (GWAS) have repeatedly identified variants at the *TMEM106B* locus that influence risk for multiple neurodegenerative diseases [1–3]. These variants are in complete linkage disequilibrium (LD), forming an LD-block that defines two haplotypes. The risk haplotype has a frequency of ~59% in European populations, and has been associated with various neurodegenerative diseases, including Alzheimer's disease [3] and frontotemporal dementia [1,2]. The reciprocal protective haplotype carries the alleles associated with protection against these traits, and occurs at a frequency of approximately ~41%.

We recently observed that the protective haplotype is among the most enriched AD-associated loci in cognitively healthy centenarians [4]. This enrichment suggests that *TMEM106B* may contribute to preserved cognitive function into extreme old age. Importantly, recent neuropathological analyses indicate that *TMEM106B* variants are primarily associated with TDP-43-related pathologies (including LATE-NC and HS) [5]; tau tangles [5,6]; and aggregation of TMEM106B fibrils [7–9]. This raises the possibility that the enrichment of the protective haplotype in centenarians reflects protection against neurodegeneration mediated by these proteinopathies. Consistent with this, a subset of centenarians from the 100-plus cohort exhibited TDP-43 aggregates in the brain, and TDP-43 positivity was associated with reduced cognitive performance [10].

The specific causal variants underlying the effects in the *TMEM106B* haplotypes remain unresolved [11,12]. One candidate is the missense variant rs3173615 (C>T), which results in a Thr185Ser substitution. The risk-associated rs3173615-C allele encodes threonine at position 185 and has been hypothesized to alter glycosylation, potentially influencing protein stability or aggregation propensity [13]. Indeed, carriers of the risk haplotype exhibit higher levels of

TMEM106B C-terminal aggregates compared to carriers of the rs3173615-G allele (185-Ser) [7–

9]. However, knock-in of the homologous rs3173615-G allele in mice did not confer protection

[12], suggesting that this variant alone may not explain disease risk. The risk haplotype contains

multiple additional variants in complete LD with rs3173615-C that could contribute to functional

differences. These include an AluYb8 insertion in the 3′ untranslated region (3′ UTR) [14–16] and

a variant affecting CTCF binding near rs1990620 [17], both of which may influence transcriptional

or post-transcriptional regulation of *TMEM106B*.

Despite consistent GWAS associations, the genetic architecture underlying the *TMEM106B* locus

remains incompletely resolved. In particular, variants within the locus are typically inherited in

strong linkage disequilibrium, complicating efforts to disentangle independent signals and identify

functional alleles. Moreover, structural variants (SVs), including genomic rearrangements,

tandem repeats, and transposable elements, are largely invisible to conventional imputation-

based approaches and may contribute to haplotype-specific effects that remain unexplored.

Here, we refine the *TMEM106B* locus by integrating long-read sequencing and large-scale GWAS

summary statistics with haplotype analyses in cognitively healthy centenarians, AD cases, and

age-matched controls.

METHODS

Study population

Samples used in this study included a total 5,873 genomes: 443 centenarians from the 100-plus

Study [18]; 2,321 Alzheimer disease (AD) patients from the Amsterdam Dementia Cohort [19] and

the Netherlands Brain Bank [20]; and 3,109 non-demented controls age-matched with the AD

patients previously described [4], including 1,614 from LASA cohort [21]. The Medical Ethics

Committee of the Amsterdam University Medical Center approved all studies. All participants

and/or their legal representatives provided written informed consent for participation in clinical

and genetic studies.

Genotyping and AD-GWAS summary statistics

Array-based genotyping and haplotype-imputations of the above cohorts were previously

described [4].

We analyzed GWAS variants within 100 Kbp upstream and downstream of *TMEM106B* coding

sequence (chr7:12111294-12343367), using the latest AD-GWAS summary statistics [22].

Pairwise linkage disequilibrium (LD) values (r^2) were calculated with PLINK (v2.00a6LM) [23]

using the centenarian, AD-cases, and control cohorts described above, and variants were

clumped using a conservative r^2 threshold of 0.15. We retained the sentinel SNPs of LD blocks

with genome-wide significance in the AD-GWAS (p-value < 5.5×10^{-8}). We define an LD block as

a set of variants that were in strong LD ($r^2 \geq 0.8$) with the sentinel SNPs, resulting in two blocks:

Block 1 (marked by rs5011439) and Block 2 (rs13237415). To avoid overestimation in

downstream analysis, we additionally performed pairwise LD between all variants within each LD

block, and identified a representative SNP for each block via hierarchical clustering, resulting in

two medoid-based marker SNPs for Block 1 (rs12699338) and Block 2 (rs12699361). Joint effect

analyses using GCTA-COJO (v1.94.1) [24] were performed separately for (i) sentinel SNPs from

each block; and (ii) the corresponding medoid SNPs, confirming that both sets show independent

associations.

Differential enrichment of TMEM106B haplotype in centenarians

Using the array-imputed haplotypes of the 5,873 genomes (11,746 total haplotypes), we used the

sentinel SNPs to classify *TMEM106B* haplotypes (T1-T4), as detailed in Table S1.

To determine whether individual haplotypes and their genotypes were enriched in centenarians,

we used logistic regression models implemented in R (v4.5.2) with the *glm* function by separately

comparing centenarians with non-demented controls and AD-cases. All models were adjusted for

APOE genotype (modeled as categorical factors) and population structure using the first five

genetic principal components calculated with PLINK.

For the enrichment analysis of individual haplotypes, we applied a weighted sum-to-zero (effect)

encoding in a joint model to test the independent enrichments of the T1-T4 haplotype. This

approach enables estimation of the independent effect of each haplotype relative to the

frequency-weighted average effect across all haplotypes, allowing effect sizes (β), standard

errors, 95% confidence intervals, and p-values to be interpreted on a common scale. Briefly, we

fitted a joint logistic regression model with centenarian phenotype as the response variable,

Centenarian ~ T2 + T3 + T4 + APOE + PC$_{1-5}$, using T1 as the reference level. We then used the

estimated β's and their variance-covariance matrix to compute the frequency-weighted average

effect across all haplotypes, including T1, where weights were defined by haplotype frequencies

in 5,873 array-imputed genomes. We re-expressed the haplotype-specific β's under a weighted

sum-to-zero constraint, and applied Wald tests to evaluate whether each haplotype significantly

deviated from the weighted average effect.

To determine specific genotypes of the *TMEM106B* haplotypes, we constructed a categorical

variable representing all observed genotypes (e.g., T1/T1, T1/T2, T2/T3, etc.). We then fitted a

joint logistic regression model using T1/T1 as the reference genotype, adjusting for *APOE*

genotype and genetic PC$_{1-5}$. Due to the relative low frequency of T4, we adjusted for but not

interpreted estimated effects T4-containing genotypes. Odds ratios and 95% confidence intervals

were calculated from the regression coefficients.

To account for multiple testing, we defined two families of tests: (i) enrichment of individual

haplotypes and (ii) enrichment of genotypes. We controlled the false discovery rate (FDR) within

each family using the Benjamini–Hochberg procedure (family i: 8 tests; family ii: 10 tests). FDR-

adjusted q-values <0.1 were considered statistically significant. Adjusted q-values are reported

alongside nominal p-values.

Long-read sequencing of 493 Dutch genomes

Peripheral blood tissue of a subset of 245 CHCs and 248 ADCs were long-read whole-genome

sequenced on Pacific Biosciences (PacBio) Sequel IIe System. For 10 centenarians, we long-

read whole-genome sequenced temporal brain tissue. All samples were sequenced at the

Department of Clinical Genetics at the Amsterdam University Medical Center (AUMC) and at the

Radboud Technology Genome Center and Radboud University Medical Center (RUMC), using 2

hours of pre-extension time and 30 hours of collection time. Overall, the AD and centenarian

genomes were sequenced at a median coverage of 18.2x, with median read-lengths of 14.8 Kbp.

See extended details in **Supplemental Methods**.

After sequencing, raw reads were collected and analyzed through an in-house pipeline (freely

available at https://github.com/holstegelab/snakemake_pipeline; Supplemental Methods).

In addition, we used publicly available HiFi-based 47 whole-genomes from the Human

Pangenome Research Consortium, which were similarly processed through our in-house pipeline

(**Supplemental Methods**).

Variant and methylation profiles using long-read sequencing data

Single nucleotide polymorphisms (SNPs) were identified in both the ADC and CHC long-read

sequencing data using *deepvariant* (v1.1.0) [25], and joint-called using *GLnexus* (v1.4.1-0-

g68e25e5) using '--config Deepvariant' parameter [26].

Structural variants (SVs) in AD cases, centenarians, and HPRC genomes were identified and

genotyped using an in-house local assembly pipeline based on Sniffles2 (v2.0.6) [27] and Otter

(v1.0) [28] (**Supplemental Methods)**. The pipeline comprises three steps.

First, we performed local assembly of allele sequences for each candidate SV in each genome.

Second, we conducted joint genotyping across genomes using a fast sequence-based clustering

procedure implemented in Otter (**Supplemental Results**), enabling direct comparison and

harmonization of SV allele sequences across >1 million SV regions and large collections of long-

read genomes. This step generated an SV-based gVCF for the centenarian and AD genomes.

Third, we recalibrated SV genotypes by probabilistically inferring the most likely genotype based

on supporting long-read alignments, together with a corresponding genotype quality (GQ) score,

using the *svg* function in Haplr (v0.1.0) (https://github.com/holstegelab/haplr), enabling consistent

genotyping across both high-coverage and low-coverage samples. Additionally, this procedure

also quantifies CpG methylation within each SV-allele.

The corresponding allele-sequence of all unique genotypes of all SVs were annotated using

DFAM (release 3.7) [29] to annotate transposable elements (TEs), while tandem repeats (TRs)

were annotated by overlapping TR-annotation tracks from the UCSC Genome Browser

(http://genome.ucsc.edu) [30].

To evaluate haplotype-specific structural variants (SVs) and CpG methylation, reads were phased

using the *svg* and *mtp* functions in Haplr. GWAS variants defined in (**Table S1**), enabling

assignment of SV alleles and CpG methylation to specific haplotypes.

For methylation analyses, we focused on CpG sites within the start/end coordinates from the

union of both LD blocks (chr7:12146976-12247317). CpG sites were retained if they had a

minimum per-sample coverage of 4 reads and were observed in at least 10 independent

individuals. Methylation levels were calculated per individual and haplotype as the fraction of

methylated reads over total reads. CpG methylation was summarised separately for each pairwise

haplotype-comparison (T1 vs T2; T1 vs T3; and T2 vs T3) across individuals, and sites with at

least 10% median methylation between haplotypes ($|\Delta$ methylation$| \geq 0.1$) were considered

differentially methylated CpG sites, and those with a 90% difference ($|\Delta$ methylation$| \geq 0.9$) were

considered haplotype-specific. Regulatory annotation was incorporated using candidate cis-

regulatory element (cCRE) tracks from ENCODE (dataset ENCFF924IMH) [31].

RESULTS

Two independent LD blocks in the TMEM106B locus are associated with Alzheimer's disease

(AD)

To explore whether additional haplotypes, next to the known risk and protective haplotypes also

associated with AD-risk, we used linkage disequilibrium (LD) profiles from 5,873 Dutch genomes

comprising of cognitively healthy centenarians, AD-cases, and age-matched controls to analyze

the summary statistics of the most recent AD-GWAS [22] (~978K participants; **Figure 1A**). We

restricted analyses to common variants that (i) surpassed genome-wide significance in their

associations with AD ($p \leq 5.5 \times 10^{-8}$), (ii) had minor allele frequency $\geq 1\%$, and (iii) clustered within

multi-SNP LD blocks defined by $r^2 \geq 0.15$ (see **Methods**).

A) Alzheimer's disease GWAS (978K individuals)

B) Observed haplotypes in array-imputations (n=5,873)

C) Haplotype enrichment in centenarians

D) Genotype enrichment in centenarians (relative to T1/T1)

Figure 1. Four separate *TMEM106B* haplotypes are differentially associated with risk for Alzheimer's disease (AD) and extreme

cognitive preservation. (A) LocusZoom plot of the *TMEM106B* locus in the latest AD-GWAS [22] highlighting conditionally

independent LD blocks. Top: Block 1 encompassing the known risk and protective haplotypes which harbour alleles previously

associated with risk to various neurodegenerative traits and pathologies, marked by rs5011439. Bottom: Block 2 encompassing novel

risk and protective haplotypes marked by rs13237415 with similar effects as Block 1. **(B)** The alleles from both blocks are inherited in

four specific haplotypes, T1-T4, as observed in 5,873 Dutch genomes. **(C-D)** Enrichment analysis of the haplotypes when comparing

centenarians with controls or AD-cases. FDR-adjusted p (10% threshold): *** < 0.01; ** < 0.05; * < 0.1. **(C)** At the individual haplotype

level, T3 is significantly enriched in centenarians, while T1 is significantly depleted. **(D)** Relative to T1/T1 homozygous carriers, the

T2/T3 genotype is significantly enriched in centenarians.

Two independent LD-blocks at *TMEM106B* reached genome-wide significance (**Figure 1A**).

Block 1 (marker SNP rs5011439-C; AF=43%, OR=0.96, p=1.9x10^{-13}) overlaps the *TMEM106B*

coding region and corresponds to known risk and protective haplotypes (risk: rs5011439-G;

protective: rs5011439-C). Block 2, marked by SNP rs13237415-T (AF=9%, OR=0.94, p=7.7x10^{-}

^{9}), spans ~65 kb upstream to ~25 kb downstream of *TMEM106B* (**Figure 1A**). The blocks are

largely independent (r^2=0.11), and each remained significant in joint/conditional GCTA-COJO

analyses (OR=0.96 for both; p=6.4x10^{-9} and 3.3x10^{-4}), even when extending to other marker

SNPs in their respective LD blocks (**Methods**). All SNPs in Block 2 are in strong LD (r^2≥0.8; **Table**

S1), defining two additional haplotypes with rs13237415-G associated with risk and rs13246024-

T with protection.

Together, these findings establish that the *TMEM106B* locus comprises two conditionally

independent association signals, each defined by distinct haplotypes.

Four TMEM106B haplotypes are differentially enriched in cognitively healthy centenarians

The allele combination of the sentinel SNPs of blocks 1 and 2 define four haplotypes across all

genomes (n=11,746; **Figure 1B and Table S1**). We refer to these haplotypes as T1-T4 in

descending frequency: T1 is the most common combination (57%, n=6,701) and contains the

risk-associated alleles of both blocks. T2 follows (33%, n=3,919) and carries the protective alleles

of block 1 and risk alleles of block 2. T3 (9%, n=1,020) carries protective alleles from both blocks,

and T4 (~1%, n=106) carries risk alleles from block 1 and protective alleles from block 2.

We found that, compared with non-demented controls, carriers of T3 were significantly associated

with a 1.42-fold higher odds of being a centenarian (OR=1.42, 95% CI=[1.14,1.76]; p=0.002;

q=0.007). In contrast, T3 was significantly depleted in centenarians, with a 0.9-fold lower odds

(OR=0.90, CI=[0.84,0.96]; p=7.43×10^{-4}; q=0.006). T2 had modest significant enrichment

(OR=1.10, CI=[0.99,1.21]; p=0.070; q=0.093), while enrichment for T4 was imprecise due to its

relative low frequency (OR=1.03, CI=[0.49,2.16]; p=0.944; q=0.944).

To further disentangle the contribution of the 185-Serine-encoding haplotypes, we repeated the

analysis using T2mthe most frequent serine-containing haplotype, as the reference. Under this

model, T1 remained depleted (OR=0.82, CI=[0.70,0.96]; p=0.012), while T3 remained enriched

(OR=1.29, CI=[1.00,1.66]; p=0.048), indicating that the enrichment of T3 cannot be explained by

the serine allele alone and may reflect additional protective features. Similar patterns were

observed when comparing centenarians with AD cases, although effect sizes were attenuated

(Figure 1C).

Analogous to the genotype-specific effects observed for ε4/ε4, ε4/ε3, and ε4/ε2 at *APOE*, we next

examined the *TMEM106B* genotypes in centenarians. To do this, we fitted a logistic regression

model relative to T1/T1 homozygous carriers, the genotype with the most depleted haplotype.

This analysis reinforced the prominent role of T3 (**Figure 1D**): the heterozygous T2/T3 genotype

had a 2.10-fold significantly higher odds of becoming a centenarian (OR=2.10, CI=[1.39,3.20];

p=4.82×10^{-4}; q=0.005), and significantly increased to 2.92 for the homozygous T3/T3 although

with wide confidence intervals (OR=2.92, CI=[1.01,8.40]; p=0.047; q=0.084). Other genotypes,

including T1/T2, T1/T3, and T2/T2, showed more modest but significant enrichments (**Figure 1D**).

In contrast, estimates for genotypes containing T4 were imprecise due to its low frequency.

Similar patterns were observed when comparing centenarians with AD cases, although effect

sizes were attenuated (**Figure 1D**). All associations were adjusted for *APOE* genotype status.

Long-read fine-mapping reveals haplotype-specific structural variants in TMEM106B

To fine-map the genetic basis of the differential associations observed for the T1-T4 *TMEM106B*

haplotype, we performed long-read whole-genome sequencing of 493 individuals, including 245

AD-cases from the ADC cohort and 248 cognitively healthy centenarians from the 100-plus Study

(**Methods**). We used these data to characterize haplotype-resolved structural variation and DNA

methylation patterns of the different haplotypes spanning *TMEM106B*.

We found eight total common structural variants (SVs, ≥25 bp, ≥1% frequency). The SVs ranged

from 35 bp to ~19 Kbp (**Figure 2A**), with allele frequencies spanning ~10–90%, similar to those

of the two LD blocks (**Table S1**). In addition to the previously reported AluYb8 insertion in the

3′UTR, we identified seven novel SVs. The largest was a ~19 Kbp genomic rearrangement located

~51 Kbp upstream of the *TMEM106B* transcription start site, likely mediated by an AluYh3

element (**Figure 2B**). Among the identified SVs, a multi-allelic tandem repeat (TR_12157495)

located near the rearrangement directly overlapped a known distal enhancer (EH38E2534480),

suggesting potential regulatory relevance.

Both LD-based analyses and long-read phasing independently supported haplotype-specific

associations for four SVs (**Figure 2C and 2D**): the AluYb8 insertion was linked to T1 and T4; and

the ~19 Kbp rearrangement, along with contractions in TR_12157495 and expansions

TR_12159254, were linked to T3 and T4 (**Figure 2C**). The AluYb8 insertion and the ~19 Kbp

rearrangement were both highly methylated (**Figure 2D**), highlighting possible regulatory effects.

We note that while haplotypes T1-T4 are predominantly present in European (Dutch) ancestry,

we observed additional haplotypes with distinct allelic combinations in genomes with African

ancestry (**Supplemental Results**), consistent with prior work highlighting differences in LD

structure in the *TMEM106B* locus between genomes with European and African ancestry [32].

This includes a distinct haplotype with the risk-associated 185-Threonine, and the protective-

associated absence of the AluYb8 element (**Figure S1**).

These findings indicate that although both T2 and T3 carry the 185-serine allele, T3 uniquely

harbors multiple SVs located ~51 Kbp upstream of *TMEM106B* (**Figure 2E**). These haplotype-

specific SVs may contribute to the preferential enrichment of T3 observed in centenarians.

Functional studies will be required to determine the biological consequences of these variants.

Figure 2. The *TMEM106B* haplotypes are characterized by large structural variation (SVs). (A) Landscape of SVs in the *TMEM106B* locus using 493 long-read sequenced genomes. **(B)** The largest SV was a ~19 Kbp genomic rearrangement likely mediated by an AluYh3 element. **(C)** LD values (r^2) between the SVs and the SNP-markers for the Block 1 and Block 2. **(D)** Long-read phasing

and CpG methylation of allele-sequences for SVs in moderate LD ($r^2 \geq 0.6$) with either Block 1 or Block 2. **(E)** These analyses highlight

that SVs distinctly characterize the T1-T4 haplotypes of *TMEM106B*.

The TMEM106B haplotypes have distinct methylation profiles

We next investigated whether *TMEM106B* haplotypes harbor distinct DNA methylation profiles

using CpG methylation frequencies derived from haplotype-resolved long-read sequencing data.

Pairwise comparisons of the common haplotypes (T1, T2, and T3) identified 146 unique CpG

sites that were differentially methylated in at least one comparison (median methylation difference

≥10%), of which 129 showed near-complete haplotype-specific methylation (median difference

≥90%) (**Figure 3A and Table S2**). Many of these differences were driven by SNPs that created

or disrupted CpG dinucleotides, indicating haplotype-specific CpG content (**Table S2**). This

included CpGs overlapping known distal enhancers: two linked to T1, three linked to T2, and four

linked to T3. Notably, these differentially methylated CpG sites led to higher methylation in the

intronic regions (introns 3 and 4) and the 3' UTR in T1, including the AluYb8 element; along with

low methylation in T3 in the region overlapping the known rearrangement (**Figure 3A**).

As the long-read sequencing data were derived from blood, we examined whether similar

methylation patterns were observed in temporal cortex tissue by performing long-read sequencing

on paired brain samples from 10 centenarians (**Figure 3B**). Across 15 distinct haplotypes, we

identified 301 unique CpG sites that were differentially methylated between brain and blood

(absolute median methylation difference ≥10%). Tissue-specific patterns were consistent across

haplotypes: methylation levels were higher in the brain at the transcription start site, whereas

blood showed higher methylation across introns 3 through the 3'UTR. These results indicate that

haplotype-associated methylation patterns in *TMEM106B* likely differ by tissues.

Figure 3. The *TMEM106B* haplotypes are also characterized by distinct CpG DNA

methylation profiles. **(A-B)** CpG methylation profiles derived from phased long-read sequencing

of blood samples from 493 individuals. Differentially methylated CpG sites are defined as sites

where the fraction of methylated reads is at least 10% between haplotypes. **(A)** Using differentially

methylated CpG sites (n=146), spline regression of median methylation values per common

haplotype (T1-T3) along with standard errors (colour shades), with the bottom plot illustrating the

365 canonical transcript of *TMEM106B*. **(B)** For a subset of 10 individuals, long-read whole-genome

366 sequencing was also performed on matched brain tissue (temporal cortex). Shown are per-

367 sample methylation differences between brain and blood for CpG sites exhibiting an absolute

368 methylation difference ≥10% (n=301), stratified by haplotype. Homozygous haplotype-genotypes

369 were evaluated as a single measurement.

DISCUSSION

In this study, we refine the genetic architecture of the *TMEM106B* locus and demonstrate that two conditionally independent GWAS LD blocks generate four common haplotypes (T1-T4) with differential associations with Alzheimer's disease and extreme cognitive preservation. Among these haplotypes, T3 shows the strongest enrichment in cognitively healthy centenarians, while T1 is depleted. These haplotypes are further distinguished by structural and epigenetic features, including large structural variants (SVs) and distinct DNA methylation patterns. This includes a ~19 Kbp genomic rearrangement ~51 Kbp upstream of the transcription start site of *TMEM106B* that are near and/or overlap known distal enhancers, strongly linked to T3 and T4. In addition, T1 is characterized by highly methylated CpG sites within the intronic region and 3′UTR of *TMEM106B*. Together, these findings extend previous GWAS observations and reveal a more nuanced haplotypic structure underlying *TMEM106B*-associated risk.

Our results do not pinpoint the exact causal variants underlying the associations at the *TMEM106B* locus, but instead indicate that multiple genetic mechanisms likely contribute beyond the previously emphasized amino acid substitution at residue 185 (Threonine/Serine). In particular, the role of the Serine allele and its protective associations with neurodegenerative traits has been actively debated [11,12]. Although both T2 and T3 harbor the serine allele, T3 is more strongly enriched than T2 in centenarians, suggesting that additional protective mechanisms may be encoded within the T3 haplotype. The large structural variants strongly linked to T3 represent plausible candidates for such effects; however, we note that multiple other variants, including CpG sites in regulatory elements, are also in strong linkage disequilibrium with T3 and may contribute to the observed associations.

TMEM106B has been implicated in TMEM106B fibril pathology, TDP-43-related

neurodegeneration, and tau pathology [5–9]. The presence of multiple *TMEM106B* haplotypes

raises the possibility that they may differentially influence specific pathological pathways, or exert

overlapping effects across these processes. The strong enrichment of T3 in cognitively healthy

centenarians suggests that this haplotype may contribute to preserving cognitive function [33,34],

and potentially confer protection across multiple proteinopathies. Dissecting pathology-specific

effects of individual haplotypes will require neuropathologically characterized cohorts and lies

beyond the scope of the present study.

Several limitations warrant consideration. First, our structural variant analysis focused on common

SVs (allele frequency ≥1%), and mainly in genomes with European ancestry. Rarer variants, and

non-European haplotypes may also contribute to locus heterogeneity [32]. Indeed, we observe

additional haplotypes with distinct permutations of the 185-Threonine/Serine amino acids along

with the SVs including the AluYb8 element and rearrangement. Evaluating the effects of these

novel haplotypes on disease risk is beyond the scope of this study. Second, the T4 haplotype is

relatively rare, limiting power to estimate its independent effects with precision. Third, although

we identify haplotype-specific structural and methylation differences, functional consequences

remain to be experimentally validated. The regulatory impact of the upstream rearrangement,

tandem repeats, and AluYb8 elements will require targeted functional assays.

Despite these limitations, our findings provide new insight into the genetic basis of *TMEM106B*-

associated risk and resilience. By leveraging extreme longevity as an informative phenotype and

combining haplotype-aware GWAS interpretation with long-read sequencing, we uncover

structural and epigenetic features that refine the locus beyond single-marker associations. These

results underscore the importance of haplotype-resolved analyses and structural variation in

interpreting complex disease loci and suggest that similar hidden architectures may underlie other

GWAS signals in neurodegeneration.

ACKNOWLEDGMENTS

The authors are grateful to all study participants, their family members, the participating medical

staff, general practitioners, pharmacists and all laboratory personnel involved in patient diagnosis,

blood collection, blood biobanking, DNA preparation and sequencing.

SUPPORTING INFORMATION

Supplemental results, methods, figures, and tables can be found in the companion Supplemental

Materials and Tables. Consortia members and affiliations can be found in Supplemental Materials.

DATA AND MATERIALS AVAILABILITY

Long-read sequencing data generated with PacBio Sequel 2 for the AD patients cognitively

healthy centenarians is available upon submission of a research proposal to the Alzheimer

Genetics Hub (AGH, https://alzheimergenetics.org/).

FUNDING

Part of the work in this manuscript was carried out on the Cartesius supercomputer, which is

embedded in the Dutch national e-infrastructure with the support of SURF Cooperative.

Computing hours were granted to H. H. by the Dutch Research Council ('100plus': project#

vuh15226, 15318, 17232, and 2020.030; 'Role of VNTRs in AD'; project# 2022.31, 'Alzheimer's

Genetics Hub' project# 2022.38). This work is supported by a VIDI grant from the Dutch Scientific

Counsel (#NWO 09150172010083) and a public-private partnership with TU Delft and PacBIo,

receiving funding from ZonMW and Health~Holland, Topsector Life Sciences & Health (PPP-

allowance), and by Alzheimer Nederland WE.03-2018-07. H.H., S.L., are recipients of ABOARD,

a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland,

Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). S.L. is recipient of ZonMW

funding (#733050512). H.H. was supported by the Hans und Ilse Breuer Stiftung (2020),

Dioraphte 16020404 (2014) and the HorstingStuit Foundation (2018). Acquisition of the PacBio

Sequel II long read sequencing machine was supported by the ADORE Foundation (2022).

CONSENT OF STATEMENT

The Medical Ethics Committee of the Amsterdam University Medical Center approved all studies.

All participants and/or their legal representatives provided written informed consent for

participation in clinical and genetic studies.

CONFLICT OF INTEREST STATEMENT

HH has a collaboration contract with Muna Therapeutics, PacBio, Neurimmune and Alchemab.

She serves in the scientific advisory boards of Muna Therapeutics and is an external advisor for

Retromer Therapeutics. Research of Alzheimer center Amsterdam is part of the

neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center

Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum

Amsterdam. The clinical database structure was developed with funding from Stichting Dioraphte.

REFERENCES

[1] Van Deerlin VM, Sleiman PMA, Martinez-Lage M, Chen-Plotkin A, Wang L-S, Graff-Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234–9. https://doi.org/10.1038/ng.536.

[2] Pottier C, Küçükali F, Baker M, Batzler A, Jenkins GD, Van Blitterswijk M, et al. Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing. Nat Commun 2025;16:3914. https://doi.org/10.1038/s41467-025-59216-0.

[3] Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 2022;54:412–36. https://doi.org/10.1038/s41588-022-01024-z.

[4] Tesi N, Van Der Lee S, Hulsman M, Van Schoor NM, Huisman M, Pijnenburg Y, et al. Cognitively healthy centenarians are genetically protected against Alzheimer's disease. Alzheimer's & Dementia 2024;20:3864–75. https://doi.org/10.1002/alz.13810.

[5] Shade LMP, Katsumata Y, Abner EL, Aung KZ, Claas SA, Qiao Q, et al. GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia. Nat Genet 2024;56:2407–21. https://doi.org/10.1038/s41588-024-01939-9.

[6] Vialle RA, De Paiva Lopes K, Li Y, Ng B, Schneider JA, Buchman AS, et al. Structural variants linked to Alzheimer's disease and other common age-related clinical and neuropathologic traits. Genome Med 2025;17:20. https://doi.org/10.1186/s13073-025-01444-6.

[7] T. Vicente C, Perneel J, Wynants S, Heeman B, Van Den Broeck M, Baker M, et al. C-

terminal TMEM106B fragments in human brain correlate with disease-associated

TMEM106B haplotypes. Brain 2023;146:4055–64. https://doi.org/10.1093/brain/awad133.

[8] Lee JY, Harney DJ, Teo JD, Kwok JB, Sutherland GT, Larance M, et al. The major

TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and

myelin lipid homeostasis in the ageing human hippocampus. Mol Neurodegeneration

2023;18:63. https://doi.org/10.1186/s13024-023-00650-3.

[9] Marks JD, Ayuso VE, Carlomagno Y, Yue M, Todd TW, Hao Y, et al. TMEM106B core

deposition associates with TDP-43 pathology and is increased in risk SNP carriers for

frontotemporal dementia. Sci Transl Med 2024;16:eadf9735.

https://doi.org/10.1126/scitranslmed.adf9735.

[10] Zhang M, Ganz AB, Rohde S, Lorenz L, Rozemuller AJM, Van Vliet K, et al. The

correlation between neuropathology levels and cognitive performance in centenarians.

Alzheimer's & Dementia 2023;19:5036–47. https://doi.org/10.1002/alz.13087.

[11] Jiao H-S, Yuan P, Yu J-T. TMEM106B aggregation in neurodegenerative diseases: linking

genetics to function. Mol Neurodegeneration 2023;18:54. https://doi.org/10.1186/s13024-

023-00644-1.

[12] Cabron A-S, Borgmeyer U, Richter J, Peisker H, Gutbrod K, Dörmann P, et al. Lack of a

protective effect of the Tmem106b "protective SNP" in the Grn knockout mouse model for

frontotemporal lobar degeneration. Acta Neuropathol Commun 2023;11:21.

https://doi.org/10.1186/s40478-023-01510-3.

[13] Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB, Castanedes-Casey M, et al.

TMEM 106B p.T185S regulates TMEM 106B protein levels: implications for frontotemporal

dementia. Journal of Neurochemistry 2013;126:781–91. https://doi.org/10.1111/jnc.12329.

[14] Chemparathy A, Le Guen Y, Zeng Y, Gorzynski J, Jensen TD, Yang C, et al. A 3′UTR

Insertion Is a Candidate Causal Variant at the *TMEM106B* Locus Associated With

Increased Risk for FTLD-TDP. Neurol Genet 2024;10:e200124.

https://doi.org/10.1212/NXG.0000000000200124.

[15] Rodney A, Karanjeet K, Benzow K, Koob MD. A common Alu insertion in the 3'UTR of

TMEM106B is associated with risk of dementia. Alzheimer's & Dementia

2024;20:5071–7. https://doi.org/10.1002/alz.14090.

[16] Salazar A, Tesi N, Knoop L, Pijnenburg Y, Van Der Lee S, Wijesekera S, et al. An AluYb8

retrotransposon characterises a risk haplotype of TMEM106B associated in

neurodegeneration 2023. https://doi.org/10.1101/2023.07.16.23292721.

[17] Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, et al. A

Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and

Gene Expression. The American Journal of Human Genetics 2017;101:643–63.

https://doi.org/10.1016/j.ajhg.2017.09.004.

[18] Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, et al. The 100-

plus Study of cognitively healthy centenarians: rationale, design and cohort description.

Eur J Epidemiol 2018;33:1229–49. https://doi.org/10.1007/s10654-018-0451-3.

[19] Van Der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to

Optimize Care. Journal of Alzheimer's Disease 2018;62:1091–111.

https://doi.org/10.3233/JAD-170850.

[20] The Netherlands Brain Bank for Psychiatry. Handbook of Clinical Neurology, vol. 150,

Elsevier; 2018, p. 3–16. https://doi.org/10.1016/B978-0-444-63639-3.00001-3.

[21] Hoogendijk EO, Van Schoor NM, Qi Y, Visser M, Swinkels JC, Broese Van Groenou MI, et

al. The Longitudinal Aging Study Amsterdam: design and cohort update 2025. Eur J

Epidemiol 2025;40:705–20. https://doi.org/10.1007/s10654-025-01238-5.

[22] ADGC, Bonn, CHARGE, EADB, Bellenguez C, EADI, et al. Consensus meta-analysis of

genome-wide association studies for Alzheimer's disease and related dementia 2025.

https://doi.org/10.1101/2025.10.20.25338060.

[23] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A

Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. The

American Journal of Human Genetics 2007;81:559–75. https://doi.org/10.1086/519795.

[24] Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex

Trait Analysis. The American Journal of Human Genetics 2011;88:76–82.

https://doi.org/10.1016/j.ajhg.2010.11.011.

[25] Poplin R, Chang P-C, Alexander D, Schwartz S, Colthurst T, Ku A, et al. A universal SNP

and small-indel variant caller using deep neural networks. Nat Biotechnol 2018;36:983–7.

https://doi.org/10.1038/nbt.4235.

[26] Yun T, Li H, Chang P-C, Lin MF, Carroll A, McLean CY. Accurate, scalable cohort variant

calls using DeepVariant and GLnexus. Bioinformatics 2021;36:5582–9.

https://doi.org/10.1093/bioinformatics/btaa1081.

[27] Smolka M, Paulin LF, Grochowski CM, Horner DW, Mahmoud M, Behera S, et al.

Comprehensive Structural Variant Detection: From Mosaic to Population-Level 2022.

https://doi.org/10.1101/2022.04.04.487055.

[28] Tesi N, Salazar A, Zhang Y, Van Der Lee S, Hulsman M, Knoop L, et al. Characterizing

tandem repeat complexities across long-read sequencing platforms with TREAT and *otter*.

Genome Res 2024;34:1942–53. https://doi.org/10.1101/gr.279351.124.

[29] Storer J, Hubley R, Rosen J, Wheeler TJ, Smit AF. The Dfam community resource of

transposable element families, sequence models, and genome annotations. Mobile DNA

2021;12:2. https://doi.org/10.1186/s13100-020-00230-y.

[30] Casper J, Speir ML, Raney BJ, Perez G, Nassar LR, Lee CM, et al. The UCSC Genome

Browser database: 2026 update. Nucleic Acids Research 2026;54:D1331–5.

https://doi.org/10.1093/nar/gkaf1250.

[31] The ENCODE Project Consortium, Abascal F, Acosta R, Addleman NJ, Adrian J, Afzal V,

et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes.

Nature 2020;583:699–710. https://doi.org/10.1038/s41586-020-2493-4.

[32] Katsumata Y, Fardo DW, Shade LMP, Alzheimer's Disease Genetics Consortium, Bowen

JD, Crane PK, et al. LATE-NC risk alleles (in *TMEM106B, GRN* , and *ABCC9* genes)

among persons with African ancestry. Journal of Neuropathology & Experimental

Neurology 2023;82:760–8. https://doi.org/10.1093/jnen/nlad059.

[33] Rohde SK, Luimes MC, Lorenz LMC, Fierro-Hernández P, Rozemuller AJM, Hulsman M,

et al. Amyloid-Beta Pathology and Cognitive Performance in Centenarians. JAMA Neurol

2025;82:837. https://doi.org/10.1001/jamaneurol.2025.1734.

[34] Zhang M, Ganz AB, Rohde S, Rozemuller AJM, Bank NB, Reinders MJT, et al. Resilience

and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in

centenarians: An age-continuous perspective. Alzheimer's & Dementia

2023;19:2831–41. https://doi.org/10.1002/alz.12899.

575